The SeqOIA Cooperative Health Group Selects IntegraGen As the Operator of Its Sequencing Platform as Part of the France Genom...
July 31 2018 - 2:11AM
Business Wire
Regulatory News:
IntegraGen (Paris:ALINT) (FR0010908723 -
ALINT), a company specializing in the transformation of data
from biological samples into genomic information and diagnostic
tools for oncology, today announced that it has been selected by
the Sequencing Omics Information Analysis (SeqOIA) Cooperative
Health Group (GCS) for the operation of its high throughput
sequencing platform. The SeqOIA GCS, which includes the Assistance
Publique- Hôpitaux de Paris, the Institut Curie and the Gustave
Roussy Cancer Center, communicated that it chose IntegraGen’s
proposal in response to a public tender it launched in April 2018
to identify the operator of the Group’s platform dedicated to the
production of high-throughput sequencing data.
SeqOIA is the genomic platform within the Paris Region that was
recently selected by the French Ministry of Solidarity and Health
for the implementation of a pilot project aimed at providing and
evaluating very high-throughput sequencing platform within the
France Genomic Medicine 2025 plan.
While awaiting the official notification of this decision,
IntegraGen’s team began utilizing its expertise and know-how to
mobilize resources to ensure a rapid set up and validation of the
platform. The company envisions this platform will enable the
SeqOIA GCS to become a world-wide leader in terms of
high-throughput sequencing and the associated innovative patient
care which results from this project. The platform will be
established within the premises of the former Hospital Broussais
located in the 15th district of Paris. This will be one of the two
pilot platforms associated with the France Genomic Medicine 2025
plan, which is under the leadership of AVIESAN with the support of
the French State. The objective of France Genomic Medicine 2025 is
to position France as one of the world’s leading countries in the
field of genomic medicine.
IntegraGen noted that this contract will amount to €18 million
over five years and will provide the SeqOIA GCS access to DNA
(exome and whole genome) and RNA sequencing data from patients,
primarily those suffering from cancer and rare diseases.
Bernard Courtieu, CEO of IntegraGen stated: “We at
IntegraGen are extremely proud to join the SeqOIA group and to
contribute to making SeqOIA a world class reference for the field
of Genomic Medicine as a part of the framework of the France
Genomic Medicine 2025 Plan. This is not only a major step forward
in terms of growth and profitability for IntegraGen, it is also the
acknowledgement of our know-how and expertise in this field. I
would like to especially thank all of IntegraGen’s employees and
partners who have built this tremendous amount of expertise and
whose hard work has been rewarded by the GCS.”
ABOUT INTEGRAGEN
IntegraGen is a company specializing in deciphering the human
genome and producing relevant and easily interpretable data for
academic and private laboratories. IntegraGen’s oncology efforts
provide researchers and clinicians with sophisticated tools for
analysis and therapeutic individualization of treatment approaches
allowing them to tailor therapy to the genetic profiles of
patients. As of December 31, 2017, IntegraGen had 40 employees and
had generated revenue of €6.2 million in 2017. Based in Evry
Genopole, IntegraGen also has an U.S. office in Cambridge,
Massachusetts. IntegraGen is listed on Euronext Growth (ISIN:
FR0010908723 - Ticker: ALINT - PEA-SME).
For more information, visit www.integragen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180730005857/en/
IntegraGenBernard CourtieuPresident and CEO+33 (0)1 60 91
09 00orLaurence Riot LamotteChief Financial
Officercontact@integragen.com+33 (0)1 60 91 09
00orNewCapLouis-Victor DelouvrierInvestor and Media
Relationsintegragen@newcap.eu+33 (0)1 44 71 98 53
Integragen (EU:ALINT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Integragen (EU:ALINT)
Historical Stock Chart
From Jul 2023 to Jul 2024